1.Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study.
Xuan CAI ; Haixia FU ; Xiangyu ZHAO ; Jin LU ; Qian JIANG ; Yingjun CHANG ; Xiaojun HUANG ; Xiaohui ZHANG
Chinese Medical Journal 2022;135(19):2344-2350
BACKGROUND:
Recombinant human thrombopoietin (rh-TPO) and eltrombopag are two distinct TPO receptor agonists (TPO-RAs) with different mechanisms. During the pandemic, when immunosuppressive medications are controversial, switching to another TPO-RA may be worth exploring in patients who do not benefit from their first TPO-RA. We investigated the outcomes of switching from rh-TPO to eltrombopag or vice versa in immune thrombocytopenia (ITP) patients.
METHODS:
This prospective, open-label, observational investigation included 96 adult ITP patients who needed to switch between rh-TPO and eltrombopag between January 2020 and January 2021 at Peking University People's Hospital in China. The study evaluated response rates and platelet counts at different time points after the switch, bleeding events, time to response, duration of response, and adverse events.
RESULTS:
At 6 weeks after switching, response was observed in 21/49 patients (43%) who switched for inefficacy and 34/47 patients (72%) who switched for non-efficacy-related issues. In the inefficacy group, 9/27 patients (33%) responded to eltrombopag, and 12/22 patients (55%) responded to rh-TPO. In the non-efficacy-related group, 21/26 (81%) and 13/21 (62%) patients in the eltrombopag and rh-TPO groups maintained their response rates at 6 weeks after switching, respectively. Response at 6 months was achieved in 24/49 patients (49%) switching for inefficacy and 37/47 patients (79%) switching for non-efficacy issues. In the inefficacy group, 13/27 patients (48%) responded to eltrombopag, and 11/22 patients (50%) responded to rh-TPO. In the non-efficacy-related group, 22/26 patients (85%) and 15/21 patients (71%) in the eltrombopag and rh-TPO groups maintained their response rates at 6 months after switching, respectively. Both eltrombopag and rh-TPO were well tolerated.
CONCLUSIONS:
Our study confirmed the safety and effectiveness of switching between rh-TPO and eltrombopag for ITP patients who had no response to or experienced adverse events with their first TPO-RA. When the switch was motivated by other reasons, including patient preference and platelet count fluctuations, the probability of response was high.
REGISTRATION
ClinicalTrials.gov, NCT04214951.
Adult
;
Humans
;
Purpura, Thrombocytopenic, Idiopathic
;
Thrombopoietin/adverse effects*
;
Prospective Studies
;
Recombinant Fusion Proteins
;
Receptors, Fc/therapeutic use*
;
Receptors, Thrombopoietin/therapeutic use*
;
Thrombocytopenia/chemically induced*
;
Benzoates/adverse effects*
;
Hydrazines/adverse effects*
2.Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial.
Jie WU ; Shu-Wei DUAN ; Xue-Feng SUN ; Wen-Ge LI ; Ya-Ping WANG ; Wen-Hu LIU ; Jian-Rong ZHANG ; Li-De LUN ; Xue-Mei LI ; Chun-Hua ZHOU ; Ji-Jun LI ; Shu-Wen LIU ; Yuan-Sheng XIE ; Guang-Yan CAI ; Lu MA ; Wen HUANG ; Hua WU ; Qiang JIA ; Xiang-Mei CHEN
Chinese Medical Journal 2016;129(16):1894-1903
BACKGROUNDThe efficacy and safety of telmisartan combined with clopidogrel, leflunomide, or both drugs for immunoglobulin A nephropathy (IgAN) are unclear. This study was designed to evaluate the efficacy and safety of telmisartan combined with clopidogrel, leflunomide, or both drugs for IgAN.
METHODSIt is a multicenter, prospective, double-dummy randomized controlled trial. Primary IgAN patients were recruited in 13 renal units across Beijing, China, from July 2010 to June 2012. After a 4-week telmisartan (80 mg/d) wash-in, 400 patients continuing on 80 mg/d telmisartan were randomly assigned to additionally receive placebo (Group A), 50 mg/d clopidogrel (Group B), 20 mg/d leflunomide (Group C), or 50 mg/d clopidogrel and 20 mg/d leflunomide (Group D). The 24-week intervention was completed by 360 patients. The primary endpoint was change in 24-h proteinuria at 24 weeks. A linear mixed-effect model was used to analyze the changes at 4, 12, and 24 weeks. Generalized estimating equations were used to evaluate changes in hematuria grade. This trial was registered at the Chinese Clinical Trial Registry.
RESULTSThe effects of telmisartan combined with leflunomide on changes in proteinuria (0.36 [95% confidence interval (CI) 0.18-0.55] g/d, P < 0.001), in serum uric acid (76.96 [95% CI 57.44-96.49] μmol/L, P < 0.001), in serum creatinine (9.49 [95% CI 6.54-12.44] μmol/L, P < 0.001), and in estimated glomerular filtration rate (-6.72 [95% CI-9.46 to -3.98] ml·min-1·1.73 m-2, P < 0.001) were statistically significant, whereas they were not statistically significant on changes in systolic and diastolic blood pressure and weight (P > 0.05). Telmisartan combined with clopidogrel had no statistical effect on any outcome, and there was no interaction between the interventions. No obvious adverse reactions were observed.
CONCLUSIONSTelmisartan combined with leflunomide, not clopidogrel, is safe and effective for decreasing proteinuria in certain IgAN patients.
TRIAL REGISTRATIONchictr.org.cn, ChiCTR-TRC-10000776; http://www.chictr.org.cn/showproj.aspx?proj=8760.
Adolescent ; Adult ; Benzimidazoles ; adverse effects ; therapeutic use ; Benzoates ; adverse effects ; therapeutic use ; Blood Pressure ; drug effects ; China ; Creatinine ; blood ; Female ; Glomerular Filtration Rate ; drug effects ; Glomerulonephritis, IGA ; blood ; drug therapy ; Humans ; Isoxazoles ; adverse effects ; therapeutic use ; Kidney Function Tests ; Male ; Middle Aged ; Prospective Studies ; Ticlopidine ; adverse effects ; analogs & derivatives ; therapeutic use ; Treatment Outcome ; Uric Acid ; blood ; Young Adult
3.A randomized, double-blind, double-dummy study comparing a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide 12.5 mg to telmisartan 80 mg in Chinese hypertensive patients who failed to respond adequately to telmisartan 80 mg.
Shao-xing CHEN ; Jin ZHANG ; Shao-liang CHEN ; Jun-zhu CHEN ; Xiao-wei YAN ; Yuan-nan KE ; Feng-he DU ; Cheng-zong ZHANG ; Yong-wen QIN ; Kui PU ; Ding-liang ZHU
Chinese Journal of Cardiology 2008;36(4):300-304
OBJECTIVETo evaluate the efficacy and safety of a fixed dose combination of telmisartan 80 mg plus hydrochlorothiazide (HCTZ) 12.5 mg (TH) to telmisartan 80 mg (T) in Chinese patients who failed to respond adequately to treatment with T.
METHODThis is a multi-center, randomized, double-blind, double-dummy clinical study. A total of 699 eligible hypertensive patients entered a one-week screening phase prior to the eight-week open-label T period. At the end of eight weeks, 345 patients who failed to respond to T (DBP > or = 90 mm Hg, 1 mm Hg = 0.133 kPa) were randomized to receive either TH (175 patients) or T (170 patients) for another eight weeks. Sitting and standing BP were taken 24 hours post-dose and adverse events were documented at visit with 4 weeks interval. Laboratory, ECG and physical examination were performed at screening, at baseline and at the final visit.
RESULTSAfter 8 weeks treatment, (1) The mean trough reduction in sitting diastolic blood pressure (SiDBP) from baseline in TH group was greater than that in T group (10.1 mm Hg vs 7.7 mm Hg, P = 0.0017). The mean trough reduction in sitting systolic blood pressure (SiSBP) from baseline was 14.2 mm Hg in TH group and 7.4 mm Hg in T group (P < 0.0001). (2) The mean trough reduction in standing DBP and standing SBP from baseline were significantly greater in TH group (8.7 mm Hg and 12.9 mm Hg) compared those in T group (7.3 mm Hg and 7.0 mmHg, P = 0.0350, P < 0.0001). (3) The number and percentage of responders in TH group (129, 74.6%) were significantly higher than in T group (100, 59.2%, P = 0.0016). (4) The incidence of the study drug-related adverse events was similar between TH and T group (3.5% vs. 3.6%, P > 0.05).
CONCLUSIONTH was more effective than T in patients not responded adequately to T in Chinese hypertensive patients.
Adult ; Aged ; Aged, 80 and over ; Angiotensin II Type 1 Receptor Blockers ; adverse effects ; therapeutic use ; Benzimidazoles ; adverse effects ; therapeutic use ; Benzoates ; adverse effects ; therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Hydrochlorothiazide ; adverse effects ; therapeutic use ; Hypertension ; drug therapy ; Male ; Middle Aged ; Treatment Outcome
4.Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Li-Tian YU ; Jun ZHU ; Hui-Qiong TAN ; Guo-Gan WANG ; Koon K TEO ; Li-Sheng LIU
Chinese Medical Journal 2011;124(12):1763-1768
BACKGROUNDThe results from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) indicated that the angiotensin-receptor blocker telmisartan was not inferior to the angiotensin-converting-enzyme inhibitor ramipril in reducing the composite endpoint of cardiovascular death, myocardial infarction, stroke or hospitalization for congestive heart failure in high-risk patients, and telmisartan was associated with slightly superior tolerability. The combination of the two drugs was associated with more adverse events without an increase in benefit. This study aimed to analyze the data from ONTARGET obtained from a subgroup of patients enrolled in China and to evaluate the demographic and baseline characteristics, the compliance, efficacy, and safety of the different treatment strategies in randomized patients in China.
METHODSA total of 1159 high-risk patients were randomized into three treatment groups: with 390 assigned to receive 80 mg of telmisartan, 385 assigned to receive 10 mg of ramipril and 384 assigned to receive both study medications. The median follow-up period was 4.3 years.
RESULTSThe mean age of Chinese patients was 65.6 years, 73.6% of patients were male. The proportion of patients with stroke/transient ischemic attacks at baseline in China was two times more than the entire study population (47.7% vs. 20.9%). In Chinese patients the proportion of permanent discontinuation of study medication due to cough was 0.5% in the telmisartan group, which was much less than that in the combination or the ramipril group. There were no significant differences in the incidence of primary outcome among three treatment groups of Chinese patients. More strokes occurred in Chinese patients than in the entire study population (8.5% vs. 4.5%). Greater systolic blood pressure reduction (-9.8 mmHg), and more renal function failure were noted in the combination treatment group than in the ramipril or telmisartan group (2.6% vs. 1.6% and 1.0%).
CONCLUSIONSThere was no evidence that the results of ONTARGET differed between Chinese patients and the entire study population with respect to the incidence of primary outcome, particularly safety. Compliance with study medications was good. The evidence from ONTARGET indicated that the treatment strategies in ONTARGET were applicable to patients in China.
Aged ; Angiotensin II Type 1 Receptor Blockers ; therapeutic use ; Angiotensin-Converting Enzyme Inhibitors ; therapeutic use ; Benzimidazoles ; administration & dosage ; adverse effects ; therapeutic use ; Benzoates ; administration & dosage ; adverse effects ; therapeutic use ; China ; Drug Therapy, Combination ; Female ; Heart Failure ; drug therapy ; Humans ; Male ; Middle Aged ; Ramipril ; administration & dosage ; adverse effects ; therapeutic use
5.Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major.
Hong-Ying GAO ; Qi LI ; Juan-Juan CHEN ; Guang-Fu CHEN ; Chang-Gang LI
Chinese Journal of Contemporary Pediatrics 2011;13(7):531-534
OBJECTIVETo study the effectiveness and safety of deferasirox (DFX) in the treatment of iron overload in children with β-thalassemia major.
METHODSTwenty-four β-thalassemia major children with iron overload who received regular blood transfusion were randomly enrolled. The serum feritin (SF) levels were measured in the patients after different doses of DFX treatment. The DFX treatment-related adverse events were observed. The values of cardiac MRI T2* and liver MRI T2* were compared between the patients receiving DFX treatment for 5 years and the patients treated with deferoxamine and deferiprone.
RESULTSThe patients with iron overload did not respond to DFX at the initial dose of 20-30 mg/kg•d. However, the SF level decreased significantly after the dose of DFX increased to 30-40 mg/kg•d (U=58, P<0.01). Serum liver transaminase elevation was the most common adverse effect, followed by non-progressive elevation in serum creatinine level. The mean SF level was significantly lower (1748±481 ng/mL vs 3462±1744 ng/mL; P<0.05), in contrast, the liver MRI T2* value was significantly higher (8.5±2.9 ms vs 2.7±1.9 ms; P<0.01) in patients receiving DFX treatment for 5 years than in the controls. There were no significant differences in the cardiac MRI T2* value between the two groups.
CONCLUSIONSDFX can reduce SF levels in a dose-dependent manner in children with β-thalassemia major. It can significantly lower liver iron overload but not cardiac overload. Serum liver transaminase elevation and non-progressive elevation in serum creatinine level are major adverse effects in DFX treatment.
Adolescent ; Adult ; Benzoates ; adverse effects ; therapeutic use ; Child ; Child, Preschool ; Dose-Response Relationship, Drug ; Female ; Ferritins ; blood ; Humans ; Iron Chelating Agents ; adverse effects ; therapeutic use ; Iron Overload ; drug therapy ; Male ; Transfusion Reaction ; Triazoles ; adverse effects ; therapeutic use ; beta-Thalassemia ; blood ; complications ; therapy
6.Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload.
Jun Ho JANG ; Je Hwan LEE ; Sung Soo YOON ; Deog Yeon JO ; Hyeoung Joon KIM ; Jooseop CHUNG ; Jong Wook LEE
Journal of Korean Medical Science 2013;28(11):1563-1572
Many Korean patients with transfusion-induced iron overload experience serious clinical sequelae, including organ damage, and require lifelong chelation therapy. However, due to a lack of compliance and/or unavailability of an appropriate chelator, most patients have not been treated effectively. Deferasirox (DFX), a once-daily oral iron chelator for both adult and pediatric patients with transfusion-induced iron overload, is now available in Korea. The effectiveness of deferasirox in reducing or maintaining body iron has been demonstrated in many studies of patients with a variety of transfusion-induced anemias such as myelodysplastic syndromes, aplastic anemia, and other chronic anemias. The recommended initial daily dose of DFX is 20 mg/kg body weight, taken on an empty stomach at least 30 min before food and serum ferritin levels should be maintained below 1000 ng/mL. To optimize the management of transfusion-induced iron overload, the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) reviewed the general consensus on iron overload and the Korean data on the clinical benefits of iron chelation therapy, and developed a Korean guideline for the treatment of iron overload.
Anemia, Aplastic/therapy
;
Benzoates/therapeutic use
;
Blood Transfusion/*adverse effects
;
Chelation Therapy/*methods
;
Humans
;
Iron Chelating Agents/*therapeutic use
;
Iron Overload/*therapy
;
Myelodysplastic Syndromes/therapy
;
Pyridones/therapeutic use
;
Republic of Korea
;
Triazoles/therapeutic use
7.Mechanism of protective effect of pretreatment of paeoniflorin on injured cortical neurons with corticosterone.
Yang LIU ; Guangzhi CUI ; Yanjun ZHANG ; Xiumei GAO ; Yan GAO
China Journal of Chinese Materia Medica 2010;35(18):2457-2459
OBJECTIVEUsing the method of reverse transcription-polymerase chain reaction (RT-PCR) to detect the related gene expression,with a view to clarify the principal mechanism that the neuroprotection of paeoniflorin (PF).
METHODAt the seventh day, after the pretreatment of PF (0.5, 2, 10 micromol x L(-1)), with 30 min primary cultures of neurons from the cerebral cortex of 16 days old embryo rats were injured with corticosterone (200 micromol x L(-1)). After 48 h, the methods of RT-PCR was used to detect the expression of Bcl-2, Bax, Caspase-3, BDNF mRNA.
RESULTCompared with model group, the dose of PF(2, 10 micromol x L(-1)) not only can degrade the expression of Bax, Caspase-3 mRNA, but also can raise the expression of Bcl-2, BDNF mRNA notablely (P < 0.05).
CONCLUSIONThe data indicated that the principal mechanism of prophylactic neuroprotective effect of PF on corticosterone-induced neurons damages maybe due to PF can raise the expression of apoptosis-related genes Bel-2, Bax, Caspase-3 mRNA, and also ascribe to PF can raise the expression of neurotrophic factor.
Animals ; Benzoates ; pharmacology ; Brain-Derived Neurotrophic Factor ; genetics ; metabolism ; Bridged-Ring Compounds ; pharmacology ; Caspase 3 ; genetics ; metabolism ; Cells, Cultured ; Cerebral Cortex ; cytology ; drug effects ; injuries ; metabolism ; Corticosterone ; adverse effects ; Female ; Gene Expression ; drug effects ; Glucosides ; pharmacology ; Male ; Monoterpenes ; Neurons ; drug effects ; metabolism ; Neuroprotective Agents ; pharmacology ; Proto-Oncogene Proteins c-bcl-2 ; genetics ; metabolism ; Rats ; Rats, Sprague-Dawley
8.Telmisartan reduced cerebral edema by inhibiting NLRP3 inflammasome in mice with cold brain injury.
Xin WEI ; Chen-Chen HU ; Ya-Li ZHANG ; Shang-Long YAO ; Wei-Ke MAO
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(4):576-583
The aim of this study was to investigate the possible beneficial role of telmisartan in cerebral edema after traumatic brain injury (TBI) and the potential mechanisms related to the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) pyrin domain-containing 3 (NLRP3) inflammasome activation. TBI model was established by cold-induced brain injury. Male C57BL/6 mice were randomly assigned into 3, 6, 12, 24, 48 and 72 h survival groups to investigate cerebral edema development with time and received 0, 5, 10, 20 and 40 mg/kg telmisartan by oral gavage, 1 h prior to TBI to determine the efficient anti-edemic dose. The therapeutic window was identified by post-treating 30 min, 1 h, 2 h and 4 h after TBI. Blood-brain barrier (BBB) integrity, the neurological function and histological injury were assessed, at the same time, the mRNA and protein expression levels of NLRP3 inflammasome, IL-1β and IL-18 concentrations in peri-contused brain tissue were measured 24 h post TBI. The results showed that the traumatic cerebral edema occurred from 6 h, reached the peak at 24 h and recovered to the baseline 72 h after TBI. A single oral dose of 5, 10 and 20 mg/kg telmisartan could reduce cerebral edema. Post-treatment up to 2 h effectively limited the edema development. Furthermore, prophylactic administration of telmisartan markedly inhibited BBB impairment, NLRP3, apoptotic speck-containing protein (ASC) and Caspase-1 activation, as well as IL-1β and IL-18 maturation, subsequently improved the neurological outcomes. In conclusion, telmisartan can reduce traumatic cerebral edema by inhibiting the NLRP3 inflammasome-regulated IL-1β and IL-18 accumulation.
Animals
;
Benzimidazoles
;
administration & dosage
;
Benzoates
;
administration & dosage
;
Blood-Brain Barrier
;
drug effects
;
Brain Edema
;
drug therapy
;
genetics
;
pathology
;
Brain Injuries, Traumatic
;
drug therapy
;
genetics
;
pathology
;
Caspase 1
;
biosynthesis
;
Gene Expression Regulation
;
drug effects
;
Humans
;
Inflammasomes
;
adverse effects
;
genetics
;
Interleukin-18
;
biosynthesis
;
Interleukin-1beta
;
biosynthesis
;
Male
;
Mice
;
NLR Family, Pyrin Domain-Containing 3 Protein
;
biosynthesis
;
genetics
;
Signal Transduction
;
drug effects